According to Israel’s Health Ministry, the CCP Virus (COVID-19 vaccine) developed by Pfizer and BioNTech, appears to increase the chance of young men suffering myocarditis, a heart muscle inflammation.
Previously, the ministry stated in late April that it was investigating a small number of cases of heart inflammation in people who had received Pfizer’s CCP Virus vaccine after receiving more than 60 cases, mostly in young men who had received their second dose of vaccine just a few days earlier.
Back then they did not come up with any conclusion.
On June 1, researchers found that between one in 3000 and one in 6000 men aged 16 to 24 who received the vaccine had the unusual symptom, according to a report submitted to the Israeli Ministry of Health.
“There is a probable link between receiving the second dose (of Pfizer) vaccine and the appearance of myocarditis among men aged 16 to 30,” the study found.
The majority of injury cases were mild, with patients being discharged from the hospital within four days, as is typical of myocarditis.
The Israeli Ministry of Health convened a group to study the issue in January, led by Dror Mevorach, head of internal medicine at Hadassah University Medical Center.
Mevorach and his colleagues discovered 110 cases of myocarditis among Israel’s 5 million people who had gotten two doses of the Pfizer-BioNTech vaccine in the month preceding their diagnosis, the Science reported.
His team found that 90% of the cases discovered in Israel were in men, and despite the fact that myocarditis is more common in young males, the vaccination rate was five to 25 times higher than the background rate.
Mevorach’s new research “is very suggestive of a causal nature” between the vaccine and myocarditis, for which he was certain that there was a connection.
Peter Liu, a cardiologist and chief scientific officer of the University of Ottawa Heart Institute said “It does suggest that this is, at least statistically, a real phenomenon.”
Douglas Diekema, a pediatrician and bioethicist at Seattle Children’s Hospital who has examined risk-benefit trade-offs, said that “From a parent’s perspective, this really comes down to risk perception, assessment of the data.”
“I can’t imagine it’s going to be anything that would cause medical people to say we shouldn’t vaccinate kids,” Diekema said.
Since late January, Israel has begun vaccinating teenagers aged 16 and up, and the Ministry of Health will announce soon if immunizations will be extended to children from 12 and older.
“I think they will decide to vaccinate teens, but not like with adults when there was a very clear recommendation in favor of vaccination,” Mevorach told The Times of Israel prior to its official release.
“Rather, they will say you should vaccinate your children but you should know there is the possibility of this side effect, leaving it to parents to decide. I predict that 50% of parents won’t vaccinate,” he said.
Pfizer confirmed that they are “aware of the reports of myocarditis in recipients of the Pfizer-BioNTech COVID-19 vaccine” in an emailed statement to Global News in April.
“More than 260 million people globally have now been vaccinated with the Pfizer/BioNTech COVID-19 vaccine and we have not observed a higher rate of myocarditis than what would be expected in the general population. A causal link to the vaccine has not been established,” the statement said.